Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|August 13, 2021
Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacyHsien-Hong Lin, Shih-Jer Hsu, Sheng-Nan Lu, et al.Therapeutic Advances in Medical Oncology|July 26, 2023
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity studyMing-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|October 20, 2020
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis CShih-Jer Hsu, Ming-Lung Yu, Chien-Wei Su, et al.Experimental Hematology & Oncology|June 21, 2023
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia veraJie Jin, Lei Zhang, Albert Qin, et al.Current Hematologic Malignancy Reports|July 11, 2025
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative NeoplasmsPrithviraj Bose, Zhijian Xiao, Hans C Hasselbalch, et al.Infectious Diseases and Therapy|May 21, 2024
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19Wang-Da Liu, Po-Hao Feng, Chien-Yu Cheng, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|November 21, 2022
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis CChi-Yi Chen, Wan-Long Chuang, Albert Qin, et al.Acta Haematologica|March 5, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia VeraJohn Mascarenhas, Prithviraj Bose, Christopher Hillis, et al.Journal of Hematology|April 22, 2024
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b TreatmentShan Shan Suo, Rong Feng Fu, Albert Qin, et al.Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.Pageof 5